StockNews.AI
INKT
StockNews.AI
168 days

MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

1. MiNK Therapeutics will report Q4 and 2024 results on March 18. 2. A conference call at 8:30 a.m. ET will discuss results. 3. The company advances iNKT cell therapies for cancer treatment. 4. MiNK emphasizes scalable manufacturing for off-the-shelf therapies. 5. Forward-looking statements highlight uncertainties in future performance.

Earnings
-2.08%Current Return
VS
-0.05%S&P 500
$8.792603/04 07:34 AM EDTEvent Start
$8.6103/05 02:09 PM EDTLatest Updated
5m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial results could showcase progress, affecting perceptions of potential growth, similar to past biotech company earnings impacting stock prices positively.

How important is it?

The financial results and corporate updates are critical to understanding MiNK's market position, significantly informing investor decisions.

Why Short Term?

The March 18 report will have an immediate effect on investor sentiment and stock performance, as seen with other biotech quarterly updates.

Related Companies

CRSPEDITNTLA
March 04, 2025 07:30 ET  | Source: MiNK Therapeutics NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its fourth quarter and year end 2024 financial results before the market opens on Tuesday, March 18th. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call Dial-in numbers: 646-307-1963 (New York), 800-715-9871 (USA & Canada) Conference ID: 8023784 Webcast A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at https://investor.minktherapeutics.com/events-and-presentations and via https://edge.media-server.com/mmc/p/s9hd6k7m/. About MiNK Therapeutics MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels. Forward Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q and the S-1 Registration Statement filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Investor Contact 917-362-1370 investor@minktherapeutics.com  Media Contact 781-674-4428 communications@minktherapeutics.com  

Related News